Pseudoangiosarcoma and Cutaneous Collagenous Vasculopathy in a Patient on A Bruton's Tyrosine Kinase Inhibitor

Overview

Journal JAAD Case Rep

Specialty Dermatology

Date 2024 Sep 30

PMID 39345278

Authors

Alison H Kucharik

Nina B Curkovic

Julio C Chavez

Kenneth Y Tsai

Andrew S Brohl

James M Grichnik

Affiliations

Soon will be listed here.

References

Salama S, Chorneyko K, Belovic B . Cutaneous collagenous vasculopathy associated with intravascular occlusive fibrin thrombi. J Cutan Pathol. 2013; 41(4):386-93. DOI: 10.1111/cup.12285. View

Guenther J, Vecerek N, Worswick S . Extensive ecchymotic patch in a patient with chronic lymphocytic leukemia. Int J Dermatol. 2023; 63(3):313-315. DOI: 10.1111/ijd.16801. View

Truong K, Bhattacharyya A, Kim J, Wells J . A uniquely distributed purpuric drug eruption from acalabrutinib. Australas J Dermatol. 2022; 63(2):e142-e144. DOI: 10.1111/ajd.13787. View

Salama S . Cutaneous collagenous vasculopathy: a new case series with clinicopathologic and ultrastructural correlation, literature review, and insight into the pathogenesis. Am J Dermatopathol. 2014; 37(5):368-75. DOI: 10.1097/DAD.0000000000000194. View

Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L . Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. Am J Clin Dermatol. 2020; 21(6):799-812. DOI: 10.1007/s40257-020-00535-x. View

Byrd J, Woyach J, Furman R, Martin P, OBrien S, Brown J . Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021; 137(24):3327-3338. PMC: 8670015. DOI: 10.1182/blood.2020009617. View

Liu J, Liu Z, Zhang J, Chen X, Chen J, Sui L . Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. Pharmaceutics. 2022; 14(9). PMC: 9506105. DOI: 10.3390/pharmaceutics14091876. View

Ma Y, Huang X . Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase. Proc Natl Acad Sci U S A. 1998; 95(21):12197-201. PMC: 22808. DOI: 10.1073/pnas.95.21.12197. View

Weeraratna A . RAF around the edges--the paradox of BRAF inhibitors. N Engl J Med. 2012; 366(3):271-3. DOI: 10.1056/NEJMe1111636. View

10.

Greene A, Goss J . Vascular Anomalies: From a Clinicohistologic to a Genetic Framework. Plast Reconstr Surg. 2018; 141(5):709e-717e. PMC: 5922803. DOI: 10.1097/PRS.0000000000004294. View

11.

Wang L, Tang J, Feng J, Huang Y, Cheng Y, Xu H . Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review. Front Oncol. 2022; 12:941633. PMC: 9359098. DOI: 10.3389/fonc.2022.941633. View